Capricor Therapeutics, Inc.

NASDAQ:CAPR

Biotechnology

Healthcare
$8.03 -0.50%

-$0.14 today

Market cap
$465.03M
Beta
0.37
P/E (TTM)
-13.9
EPS (TTM)
-$2.00
52W Low $4.30High $40.37

Volume 8.33M

Average 1.08M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$108.14M

FY 2025 · Annual

Net Income

-$105.04M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue244.9K2.55M25.18M22.27M0
Cost of Revenue021.82M36.45M49.97M0
Gross Profit244.9K(19.27M)(11.27M)(27.7M)0
Gross Margin100.0%-755.1%-44.8%-124.4%—
Research & Development13.57M21.82M36.45M49.97M84.45M
Selling, General & Admin7.61M10.43M12.81M14.87M22.75M
Operating Expenses21.18M10.43M12.81M14.87M108.14M
Depreciation & Amortization245.7K533.13K1.07M1.43M1.89M
EBITDA(19.78M)(28.49M)(21.22M)(39.04M)(100.11M)
EBITDA Margin-8075.5%-1116.5%-84.3%-175.3%—
Operating Income(20.94M)(29.7M)(24.08M)(42.56M)(108.14M)
Operating Margin-8549.9%-1163.9%-95.6%-191.1%—
Interest Income0521.53K1.73M2.2M6.26M
Interest Expense00003.05M
Other Income / Expenses915.92K677.85K1.79M2.1M3.1M
Income Before Tax(20.02M)(29.02M)(22.29M)(40.47M)(105.04M)
Pre-Tax Margin-8175.9%-1137.4%-88.5%-181.7%—
Income Tax Expense00000
Net Income(20.02M)(29.02M)(22.29M)(40.47M)(105.04M)
Net Margin-8175.9%-1137.4%-88.5%-181.7%—
EPS (Basic)(0.87)(1.18)(0.83)(1.15)(2.26)
EPS (Diluted)(0.87)(1.18)(0.83)(1.15)(2.26)
Weighted Avg Shares23.09M24.55M26.78M35.22M46.48M
Weighted Avg Shares (Diluted)23.09M24.55M26.78M35.22M46.48M

CAPR Earnings Waterfall · TTM

NASDAQ:CAPR · Revenue to Net Income

Key Ratios

EPS$-2.32
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-8.1
P/S Ratio0.0

Analysis

$0 of revenue converted into -$114.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.32, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
SC 13G/ASC 13G/A filingOct 14, 2026
SC 13GSC 13G filingSep 14, 2026

How much revenue does CAPR generate?

Capricor Therapeutics, Inc. (CAPR) reported $0.00 of revenue in fiscal 2025.

Is CAPR profitable?

Capricor Therapeutics, Inc. (CAPR) reported -$105.04M of net income.